Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Recommendation of “Strong Sell” by Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received an average recommendation of “Strong Sell” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $28.00.

Several research analysts have recently commented on FMS shares. Weiss Ratings downgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, April 24th. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Finally, Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 27th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares during the period. Arax Advisory Partners increased its holdings in Fresenius Medical Care AG & Co. KGaA by 121.6% during the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at about $58,000. Finally, Group One Trading LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at about $74,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Up 1.8%

FMS opened at $23.45 on Tuesday. The company has a market cap of $12.66 billion, a P/E ratio of 12.34, a P/E/G ratio of 4.15 and a beta of 0.80. The business’s 50-day moving average price is $22.25 and its 200-day moving average price is $22.84. The company has a current ratio of 1.20, a quick ratio of 0.86 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $28.96.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 EPS for the quarter. The firm had revenue of $5.34 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%. On average, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently declared an annual dividend, which was paid on Monday, June 8th. Investors of record on Friday, May 22nd were issued a dividend of $0.8716 per share. The ex-dividend date was Friday, May 22nd. This represents a yield of 402.0%. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is presently 32.11%.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.